ROR1/2는 중개 종양학에서 점점 더 중요성이 커지고 있는 신약 개발 가능한 표적입니다. Wnt 결합 수용체 pseudokinase는 촉매 활성이 없음에도 불구하고 정상 및 병적 상태에서의 기능적 과정 조절에 중요한 역할을 한다는 것이 기능적 연구와 구조적 연구를 통해 밝혀지고 있습니다. ROR1과 ROR2의 과발현은 많은 암에서 발견되었습니다. 예를 들어, 혈액암에서 CLL, MCL, B-ALL에서 ROR1 신호의 재활성화는 병기 진행과 ROR1 고양성 세포에서 AKT 신호의 활성화와 관련이 있습니다. ROR2 발현 또한 다발성 골수종에서 AKT 신호를 활성화시키는 것으로 나타났습니다.
ROR1은 종양 형성 촉진 작용, 암 특이적 발현, 세포 표면 발현, ROR1의 작용을 조절할 수 있는 약물의 이용 가능성이 입증되어 암 영역에서 이상적인 약물 표적으로 여겨지고 있습니다. ROR2도 약물 타겟으로 임상 평가 중이며, CAB ROR2 표적 ADC인 Bioatla BA3021을 포함한 여러 임상시험이 진행 중입니다.
Merck(Zilovertamab Vedotin), Octernal Therapeutics(ONCT-808), Novalgen(NVG-111, NVG-222, NVG-333), BioAtla(Ozuriftamab vedotin), CStone Pharmaceuticals(CS5001) 등 여러 주요 기업들이 ROR 억제제 개발에 참여하고 있습니다.
본 보고서는 ROR 억제제의 주요 7개국(미국, 독일, 프랑스, 프랑스, 이탈리아, 스페인, 영국, 일본) 시장을 조사 분석했으며, 각 지역 시장 규모와 예측, 현재 치료법, 신약, 미충족 수요 등의 정보를 전해드립니다.
DelveInsight's "ROR Inhibitors - Target Population, Competitive Landscape, and Market Forecast - 2034" report delivers an in-depth understanding of the ROR inhibitors, historical and competitive landscape as well as the ROR inhibitors market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
The ROR inhibitors market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM ROR inhibitors market size from 2020 to 2034. The report also covers current ROR inhibitors treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market's potential.
Study Period: 2020-2034
ROR Inhibitors Overview
The ROR-family proteins, ROR1 and ROR2, act as receptors or co-receptors for non-canonical Wnt ligands such as Wnt5a, thereby regulating cell polarity, migration, proliferation, and differentiation that are required for proper developmental morphogenesis and tissue-/organo-genesis. In the RORs subfamily, there are three members: RORa, RORB, and ROR?, encoded by RORA, RORB, and RORC, respectively. All of these receptors are transcription factors that are ligand-dependent.
ROR1 and ROR2 are tyrosine kinase-like orphan receptors that play critical roles in embryogenesis. Aberrant expression of ROR1 has been observed in a range of cancers compared to its limited expression in healthy adult tissue, which makes it a candidate target for treating these cancers. ROR1 has been demonstrated to play an oncogenic role in many tumor types and has been broadly linked with cell proliferation, stemness, Epithelial-mesenchymal Transition (EMT), and other metastatic abilities. In contrast, the role of ROR2 in carcinogenesis remains controversial, as it acts as either a tumor suppressor or a tumor promoter in different cancers.
The ROR inhibitor family of proteins includes ROR1 and ROR2, receptor tyrosine kinases. ROR1 is especially interesting to pharmacologists as it has only been observed in cancerous and embryonic cells, and never in healthy adult tissue. This makes it a strong therapeutic target for the treatment of several types of cancer. ROR1 and ROR2 are implicated in age-related diseases, including tissue fibrosis, atherosclerosis (or arteriosclerosis), neurodegenerative diseases, and cancers.
The ROR inhibitors epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented as total cases of selected indication for ROR inhibitors, total eligible patient pool for ROR inhibitors in selected indication, total treated cases in selected indication for ROR inhibitors in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom, and Japan from 2020 to 2034.
The drug chapter segment of the ROR inhibitors report encloses a detailed analysis of ROR inhibitors in different stages of development. It also helps understand the ROR inhibitors' clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.
Emerging Drugs
Zilovertamab Vedotin (MK-2140): Merck
Zilovertamab vedotin is an investigational ADC that targets ROR1. ROR1 is a transmembrane protein that is overexpressed in multiple hematologic malignancies. Merck is committed to research with zilovertamab vedotin across B-cell malignancies and is establishing a robust program of clinical trials under the name waveLINE.
In June 2025, Merck presented the data from the Phase II/III waveLINE-003 study evaluating zilovertamab vedotin, an investigational ADC that targets ROR1, plus standard of care as a treatment for patients with relapsed or refractory DLBCL at the ASCO 2025 annual meeting.
In February 2025, Merck announced the initiation of waveLINE-010, a pivotal Phase III clinical trial evaluating zilovertamab vedotin in combination with rituximab plus cyclophosphamide, doxorubicin, and prednisone (R-CHP) compared to rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) alone, for the treatment of patients with previously untreated DLBCL.
According to the JP Morgan Healthcare Conference data readout, the Phase II NCT05144841 (waveLINE-004) trial of zilovertamab vedotin for R/R DLBCL is expected by 2025. The Phase II/III NCT05139017 (waveLINE-003) trial for R/R DLBCL is anticipated between 2026 and 2027, while the Phase III NCT06717347 (waveLINE-010) trial for DLBCL is projected beyond 2028.
Ozuriftamab vedotin (BA3021): BioAtla/ Bristol-Myers Squibb
Ozuriftamab vedotin is a Conditionally Active Biologic (CAB) anti-ROR2 ADC consisting of a CAB anti-ROR2 humanized IgG1 monoclonal antibody conjugated to monomethyl auristatin E (MMAE) using a cleavable linker. Ozuriftamab vedotin is designed to specifically and reversibly bind to ROR2 in conditions found within the tumor microenvironment, thus conferring a selective binding advantage for tumors over normal cells. Upon binding of ozuriftamab vedotin to ROR2 on the surface of tumor cells, it is internalized, and the MMAE cytotoxin is released, thus killing the cancer cell. Ozuriftamab vedotin has shown promising overall response rates in SCCHN, and the FDA has granted Fast-Track designation (FTD) for ozuriftamab vedotin in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN).
According to BioAlta's Q1 2025 financial highlights, the company is utilizing FTD for additional discussions with the US FDA in treatment-refractory, metastatic HPV-positive SCCHN for guidance on a proposed Phase III study.
In May 2025, BioAlta announced a poster presentation of the Phase II trial of ozuriftamab vedotin (BA3021), a conditionally binding ROR2-ADC, in patients with heavily pretreated SCCHN at ASCO 2025.
ROR1/2 are putative druggable targets increasing in significance in translational oncology. Increasing evidence emerging from functional and structural studies points toward Wnt-binding receptor pseudokinases having a key role in regulating functional processes in normal and pathological conditions, despite their lack of catalytic activity. Overexpression of ROR1 and ROR2 has been detected in numerous cancers. For instance, in hematological cancers, the reactivation of ROR1 signaling in CLL, MCL, and B-ALL is linked to advanced disease stage and activation of AKT signaling in ROR1-high positive cells. ROR2 expression was also shown to activate AKT signaling in multiple myeloma.
ROR1 is considered an ideal druggable target for oncology because of its demonstrated pro-tumourigenic actions, cancer-specific expression, cell surface expression, and availability of drugs that can regulate ROR1 action. ROR2 is also under clinical evaluation as a drug target, with several clinical trials in progress, including one of Bioatla BA3021, a CAB ROR2-targeted ADC.
Several key companies, including Merck (Zilovertamab Vedotin), Octernal Therapeutics (ONCT-808), Novalgen (NVG-111, NVG-222, NVG-333), BioAtla (Ozuriftamab vedotin), CStone Pharmaceuticals (CS5001), and others, are involved in developing ROR inhibitors.
This section focuses on the uptake rate of potential approved and emerging ROR inhibitors expected to be launched in the market during 2025-2034.
ROR Inhibitors Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase III, Phase II, and Phase I. It also analyzes key players involved in developing targeted therapeutics.
The presence of numerous drugs at different stages is expected to generate immense opportunities for the ROR inhibitors market growth over the forecasted period.
Pipeline development activities
The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for ROR inhibitors emerging therapies.
The increasing strategic collaborations among major market players to enhance the growth of their pipeline products are anticipated to drive market expansion.
KOL Views
To keep up with current and future market trends, we take Industry Experts' opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry experts were contacted for insights on ROR's evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, drug uptake, along challenges related to accessibility.
DelveInsight's analysts connected with 25+ KOLs to gather insights; however, interviews were conducted with 10+ KOLs in the 7MM. Centers such as Penn Medicine's Hematologic Malignancies Translational Center of Excellence, UC Davis Comprehensive Cancer Center, University of Texas MD Anderson Cancer Center, etc. were contacted.
Their opinion helps understand and validate current and emerging therapy treatment patterns or ROR inhibitors market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.
Qualitative Analysis
We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the analyst's discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.
Market Access and Reimbursement
Reimbursement may be referred to as the negotiation of a price between a manufacturer and payer that allows the manufacturer access to the market. It is provided to reduce the high costs and make the essential drugs affordable. Health Technology Assessment (HTA) plays an important role in reimbursement decision-making and recommending the use of a drug. These recommendations vary widely throughout the seven major markets, even for the same drug.
In the US healthcare system, both Public and Private health insurance coverage are included. Also, Medicare and Medicaid are the largest government-funded programs in the US. The major healthcare programs including Medicare, Medicaid, the Children's Health Insurance Program (CHIP), and the state and federal health insurance marketplaces are overseen by the Centers for Medicare & Medicaid Services (CMS). Other than these, Pharmacy Benefit Managers (PBMs), and third-party organizations that provide services, and educational programs to aid patients are also present.
The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.
Key Updates on ROR Inhibitors